{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:23:29Z","timestamp":1791897809248,"version":"4.3.4"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA16346101A1, R01CA135650"],"award-info":[{"award-number":["R01CA16346101A1, R01CA135650"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK104956"],"award-info":[{"award-number":["DK104956"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00258","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:18:29Z","timestamp":1531181909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["New Directions in the Study and Treatment of Metastatic Cancer"],"prefix":"10.3389","volume":"8","author":[{"given":"Byunghee","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan C.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdravka","family":"Medarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/tbj.12596","article-title":"Molecular concordance between primary breast cancer and matched metastases","volume":"22","author":"Kroigard","year":"2016","journal-title":"Breast J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrc.2016.25","article-title":"Targeting metastasis","volume":"16","author":"Steeg","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: new concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.devcel.2016.03.015","article-title":"The complexity of translating anti-angiogenesis therapy from basic science to the clinic","volume":"37","author":"Ye","year":"2016","journal-title":"Dev Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1158\/0008-5472.CAN-11-0627","article-title":"Chemotherapy enhances metastasis formation via VEGFR-1\u2013expressing endothelial cells","volume":"71","author":"Daenen","year":"2011","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nrc2344","article-title":"Hypoxia and metabolism: hypoxia, DNA repair and genetic instability","volume":"8","author":"Bristow","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.neo.2014.07.003","article-title":"Tumor interstitial fluid pressure\u2014a link between tumor hypoxia, microvascular density, and lymph node metastasis","volume":"16","author":"Rofstad","year":"2014","journal-title":"Neoplasia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E1214","DOI":"10.1073\/pnas.1203794109","article-title":"Normalization of the tumor vasculature through oncogenic inhibition: an emerging paradigm in tumor biology","volume":"109","author":"Goel","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signalling in cancer and approaches to enforce tumour regression","volume":"441","author":"Mazure","year":"2006","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.15252\/embr.201540107","article-title":"Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis","volume":"16","author":"Madsen","year":"2015","journal-title":"EMBO Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1038\/ctg.2017.28","article-title":"Targeting the vasculature in hepatocellular carcinoma treatment: starving versus normalizing blood supply","volume":"8","author":"Liu","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm0604-649c","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":"Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner","volume":"7","author":"Chauhan","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1535-6108(04)00305-8","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/423593a","article-title":"Cancer: out of air is not out of action","volume":"423","author":"Bottaro","year":"2003","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","article-title":"Hypoxic control of metastasis","volume":"352","author":"Rankin","year":"2016","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","article-title":"Hypoxia and hypoxia-inducible factors: master regulators of metastasis","volume":"16","author":"Lu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2013.00013","article-title":"Modulators of HIF1\u03b1 and NFkB in cancer treatment: is it a rational approach for controlling malignant progression?","volume":"4","author":"Tafani","year":"2013","journal-title":"Front Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT pathway as a target for cancer treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu Rev Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1152\/physiol.00022.2015","article-title":"Oxygen sensing and homeostasis","volume":"30","author":"Prabhakar","year":"2015","journal-title":"Physiology"},{"key":"B45","first-page":"2299","article-title":"Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein","volume":"56","author":"Siemeister","year":"1996","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/32925","article-title":"Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha","volume":"392","author":"An","year":"1998","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrc2540","article-title":"The impact of O2 availability on human cancer","volume":"8","author":"Bertout","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J Clin Invest"},{"key":"B50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00441-002-0563-6","article-title":"Phenotypic characteristics of the nucleus pulposus: expression of hypoxia inducing factor-1, glucose transporter-1 and MMP-2","volume":"308","author":"Rajpurohit","year":"2002","journal-title":"Cell Tissue Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature01874","article-title":"Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL","volume":"425","author":"Staller","year":"2003","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.1038\/sj.onc.1207764","article-title":"Strict regulation of CAIXG250\/MN by HIF-1 [alpha] in clear cell renal cell carcinoma","volume":"23","author":"Grabmaier","year":"2004","journal-title":"Oncogene"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/nature04695","article-title":"Lysyl oxidase is essential for hypoxia-induced metastasis","volume":"440","author":"Erler","year":"2006","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/path.2310","article-title":"pVHL co-ordinately regulates CXCR4\/CXCL12 and MMP2\/MMP9 expression in human clear-cell renal cell carcinoma","volume":"214","author":"Struckmann","year":"2008","journal-title":"J Pathol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3993","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/qjmed\/hch074","article-title":"Hyperbaric oxygen: its uses, mechanisms of action and outcomes","volume":"97","author":"Gill","year":"2004","journal-title":"QJM"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/bjc.1995.474","article-title":"The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation","volume":"72","author":"Brizel","year":"1995","journal-title":"Br J Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1054\/bjoc.1999.0882","article-title":"Preservation of tumour oxygen after hyperbaric oxygenation monitored by magnetic resonance imaging","volume":"82","author":"Kinoshita","year":"2000","journal-title":"Br J Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1015832726054","article-title":"Change of oxygen pressure in glioblastoma tissue under various conditions","volume":"58","author":"Beppu","year":"2002","journal-title":"J Neurooncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1158\/0008-5472.CAN-15-2818","article-title":"Oxygen-enhanced MRI is a major advance in tumor hypoxia imaging","volume":"76","author":"Dewhirst","year":"2016","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2407-7-23","article-title":"Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors","volume":"7","author":"Raa","year":"2007","journal-title":"BMC Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11060-007-9407-2","article-title":"Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats","volume":"85","author":"Stuhr","year":"2007","journal-title":"J Neurooncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11523-012-0233-x","article-title":"Hyperbaric oxygen therapy and cancer\u2014a review","volume":"7","author":"Moen","year":"2012","journal-title":"Target Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e6381","DOI":"10.1371\/journal.pone.0006381","article-title":"Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model","volume":"4","author":"Moen","year":"2009","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10555-010-9224-5","article-title":"Hypoxia, inflammation, and the tumor microenvironment in metastatic disease","volume":"29","author":"Finger","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"B66","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/aor.12825","article-title":"Liposome-encapsulated hemoglobin improves tumor oxygenation as detected by near-infrared spectroscopy in colon carcinoma in mice","volume":"41","author":"Kawaguchi","year":"2017","journal-title":"Artif Organs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/aor.12354","article-title":"Liposome-encapsulated hemoglobin enhances chemotherapy to suppress metastasis in mice","volume":"38","author":"Murayama","year":"2014","journal-title":"Artif Organs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2015.04.027","article-title":"Therapeutic gas delivery via microbubbles and liposomes","volume":"209","author":"Fix","year":"2015","journal-title":"J Control Release"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1152\/jappl.1994.77.6.2874","article-title":"Oxygen transport to tissue by persistent bubbles: theory and simulations","volume":"77","author":"Burkard","year":"1994","journal-title":"J Appl Physiol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1152\/jappl.1996.81.1.500","article-title":"Relationship of oxygen content to PO2 for stabilized bubbles in the circulation: theory","volume":"81","author":"Van Liew","year":"1996","journal-title":"J Appl Physiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ultras.2008.02.003","article-title":"Sonodynamic therapy","volume":"48","author":"Tachibana","year":"2008","journal-title":"Ultrasonics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijpharm.2009.07.010","article-title":"Preparation and characterization of dextran nanobubbles for oxygen delivery","volume":"381","author":"Cavalli","year":"2009","journal-title":"Int J Pharm"},{"key":"B73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijpharm.2009.05.058","article-title":"Ultrasound-mediated oxygen delivery from chitosan nanobubbles","volume":"378","author":"Cavalli","year":"2009","journal-title":"Int J Pharm"},{"key":"B74","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1142\/S1793984410000195","article-title":"Injectable oxygen delivery based on protein-shelled microbubbles","volume":"1","author":"Swanson","year":"2010","journal-title":"Nano Life"},{"key":"B75","doi-asserted-by":"publisher","first-page":"15726","DOI":"10.1021\/la1029432","article-title":"Phospholipid-stabilized microbubble foam for injectable oxygen delivery","volume":"26","author":"Swanson","year":"2010","journal-title":"Langmuir"},{"key":"B76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10555-013-9461-5","article-title":"The promise of sonodynamic therapy","volume":"33","author":"Trendowski","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2015.02.004","article-title":"Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours","volume":"203","author":"Mcewan","year":"2015","journal-title":"J Control Release"},{"key":"B78","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.biomaterials.2015.11.033","article-title":"Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle","volume":"80","author":"Mcewan","year":"2016","journal-title":"Biomaterials"},{"key":"B79","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B83","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.surg.2013.05.004","article-title":"Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer","volume":"154","author":"Yamada","year":"2013","journal-title":"Surgery"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1245\/s10434-014-3779-2","article-title":"Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma","volume":"21","author":"Yamada","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/jso.23564","article-title":"Epithelial-to-mesenchymal transition predicts prognosis in clinical gastric cancer","volume":"109","author":"Murai","year":"2014","journal-title":"J Surg Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e0163162","DOI":"10.1371\/journal.pone.0163162","article-title":"Prognostic values of vimentin expression and its clinicopathological significance in non-small cell lung cancer: a meta-analysis of observational studies with 4118 cases","volume":"11","author":"Ye","year":"2016","journal-title":"PLoS One"},{"key":"B87","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.tips.2014.06.006","article-title":"Targeting EMT in cancer: opportunities for pharmacological intervention","volume":"35","author":"Davis","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"aad3680","DOI":"10.1126\/science.aad3680","article-title":"Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability","volume":"351","author":"Pattabiraman","year":"2016","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","first-page":"22143","DOI":"10.1074\/jbc.M115.641092","article-title":"Lysophosphatidic acid initiates epithelial to mesenchymal transition and induces beta-catenin-mediated transcription in epithelial ovarian carcinoma","volume":"290","author":"Burkhalter","year":"2015","journal-title":"J Biol Chem"},{"key":"B92","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ccr.2009.03.027","article-title":"Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases","volume":"15","author":"Liu","year":"2009","journal-title":"Cancer Cell"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1194\/jlr.M053462","article-title":"Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice","volume":"55","author":"Tang","year":"2014","journal-title":"J Lipid Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1021\/acs.jmedchem.6b01270","article-title":"Highly potent non-carboxylic acid autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast cancer stem cells","volume":"60","author":"Banerjee","year":"2017","journal-title":"J Med Chem"},{"key":"B95","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1541-7786.MCR-14-0263","article-title":"Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis","volume":"13","author":"Lee","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1681\/ASN.2007020196","article-title":"LPA1 receptor activation promotes renal interstitial fibrosis","volume":"18","author":"Pradere","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","article-title":"Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition","volume":"30","author":"Nakagawa","year":"2016","journal-title":"Cancer Cell"},{"key":"B99","first-page":"1410","article-title":"Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models","volume":"62","author":"Azuma","year":"2002","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1158\/0008-5472.CAN-17-1423","article-title":"Targeting the SphK1\/S1P\/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis","volume":"78","author":"Nagahashi","year":"2018","journal-title":"Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"8458","DOI":"10.1158\/1078-0432.CCR-05-0447","article-title":"FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e32380","DOI":"10.1371\/journal.pone.0032380","article-title":"FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"B103","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1186\/1471-2407-14-783","article-title":"FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling","volume":"14","author":"Lu","year":"2014","journal-title":"BMC Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nature20792","article-title":"Genome-wide in vivo screen identifies novel host regulators of metastatic colonization","volume":"541","author":"van der Weyden","year":"2017","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.tips.2015.04.006","article-title":"New therapeutic targets for cancer bone metastasis","volume":"36","author":"Krzeszinski","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"B106","first-page":"570","article-title":"The vicious cycle of bone metastases","volume":"2","author":"Guise","year":"2002","journal-title":"J Musculoskeletal Neuronal Interact"},{"key":"B107","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B108","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/annonc\/mdg194","article-title":"Bisphosphonates: new antiangiogenic molecules in cancer treatment?","volume":"14","author":"Vincenzi","year":"2003","journal-title":"Ann Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/02841860701233435","article-title":"The use of bisphosphonates in cancer patients","volume":"46","author":"Wu","year":"2007","journal-title":"Acta Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4161\/cbt.22274","article-title":"Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid","volume":"13","author":"Misso","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm3010001","article-title":"Treatment and prevention of bone metastases from breast cancer: a comprehensive review of evidence for clinical practice","volume":"3","author":"Li","year":"2014","journal-title":"J Clin Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2013.03.034","article-title":"Denosumab in breast cancer treatment","volume":"717","author":"Drooger","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"B116","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13046-017-0578-1","article-title":"Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials","volume":"36","author":"Gdowski","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00262-016-1898-2","article-title":"Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial","volume":"65","author":"Ascierto","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B127","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Addiction to oncogenes \u2013 the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1101\/gad.1204904","article-title":"Hypoxia and defective apoptosis drive genomic instability and tumorigenesis","volume":"18","author":"Nelson","year":"2004","journal-title":"Genes Dev"},{"key":"B129","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The landscape of cancer genes and mutational processes in breast cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"key":"B130","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature06174","article-title":"Tumour invasion and metastasis initiated by microRNA-10b in breast cancer","volume":"449","author":"Ma","year":"2007","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","first-page":"20541","DOI":"10.1074\/jbc.M110.121012","article-title":"miR-10b targets Tiam1: implications for Rac activation and carcinoma migration","volume":"285","author":"Moriarty","year":"2010","journal-title":"J Biol Chem"},{"key":"B132","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-013-1047-0","article-title":"Oncogenic effects of miR-10b in glioblastoma stem cells","volume":"112","author":"Guessous","year":"2013","journal-title":"J Neurooncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/onc.2012.173","article-title":"Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis","volume":"32","author":"Yigit","year":"2013","journal-title":"Oncogene"},{"key":"B134","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1158\/0008-5472.CAN-15-0888","article-title":"Combining miR-10b\u2013targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer","volume":"75","author":"Yoo","year":"2015","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/srep45060","article-title":"Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer","volume":"7","author":"Yoo","year":"2017","journal-title":"Sci Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:18:38Z","timestamp":1531181918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":135,"alternative-id":["10.3389\/fonc.2018.00258"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00258","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"article-number":"258"}}